Drug Information

Drug (ID: DG01826) and It's Reported Resistant Information

• Name: Andrographolide
• Synonyms: Andrographolide; 5508-58-7; Andrographis; UNII-410105JHGR; CHEBI:65408; (S,E)-4-Hydroxy-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethylidene)dihydrofuran-2(3H)-one; 410105JHGR; 3alpha,14,15,18-tetrahydroxy-5b,9bH,10a-labda-8(20),12-dien-16-oic acid gamma-Lactone; (3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one; 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one; Andro; (1R-(1-alpha(E(S)),4abeta,5alpha,6alpha,8aalpha))-3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)ethylidene)dihydro-4-hydroxy-2(3H)-furanone; (3E,4S)-3-{2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-decahydronaphthalen-1-yl]ethylidene}-4-hydroxyoxolan-2-one; (3E,4S)-4-hydroxy-3-{2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidenedecahydronaphthalen-1-yl]ethylidene}dihydrofuran-2(3H)-one; HMPL-004; NSC383468; NSC-383468; NCGC00095597-01; EINECS 226-852-5; NSC 383468; Andrographolide, 98%; DSSTox_CID_25980; DSSTox_RID_81270; DSSTox_GSID_45980; HMPL004; BIDD:ER0530; CHEMBL186141; GTPL9675; MEGxp0_000978; DTXSID3045980; SCHEMBL12056309; ACon1_002113; ACT03252; Andrographolide, analytical standard; HY-N0191; ZINC3881797; Tox21_111508; BDBM50084419; MFCD07778082; AKOS015920075; CCG-208428; CS-3334; DB05767; MCULE-5521128905; NCGC00179817-01; NCGC00179817-02; 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)-; AS-13637; CAS-5508-58-7; C20214; J10022; 508A587; A830479; Q-100624; Q4759444; BRD-K89282837-001-01-0; Andrographolide, United States Pharmacopeia (USP) Reference Standard; (3E)-3-[2-[(1R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-decalin-1-yl]ethylidene]-4-hydroxy-tetrahydrofuran-2-one;Andrographolide; (3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-decalin-1-yl]ethylidene]-4-hydroxy-tetrahydrofuran-2-one; (5beta,9R,10alpha,14S)-3alpha,14,15,18-Tetrahydroxylabdane-8(20),12-diene-16-oic acid gamma-lactone; (S,E)-4-Hydroxy-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethylidene)dihydrofuran-2; 2(3H)-Furanone, 3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)ethylidene)dihydro-4-hydroxy-, (1R-(1-alpha(E(S*)),4a-beta,5-alpha,6-alpha,8a-alpha))-; 2(3H)-Furanone,3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-,(3E,4S)-
• Indication:
  In total 1 Indication(s)
  Bacillary dysentery [ICD-11: 1A02]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
  Pulmonary hypertension [ICD-11: BB01]; [1]
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Chronic obstructive pulmonary disease [ICD-11: CA22]; [1]
• Target: .; NOUNIPROTAC; [1]
• Formula: 3
• IsoSMILES: C[C@@]12CC[C@H]([C@@]([C@H]1CCC(=C)[C@H]2C/C=C/3\\[C@@H](COC3=O)O)(C)CO)O
• InChI: InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1
• InChIKey: BOJKULTULYSRAS-OTESTREVSA-N
• PubChem CID: 5318517
• ChEBI ID: CHEBI:65408
• TTD Drug ID: D04VIS
• DrugBank ID: DB05767

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-11: Circulatory system diseases

Pulmonary hypertension [ICD-11: BB01]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: HOX transcript antisense RNA (HOTAIR) [1]

• Molecule Alteration: Up-regulation; Expression
• Resistant Disease: Pulmonary dysfunction [ICD-11:BB01.1]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: HBECs; Bronchus; Homo sapiens (Human); CVCL_0287
• In Vivo Model: Male BALB/c mice CS-exposed model; Mus musculus
• Experiment for Drug Resistance: Annexin V-PI Apoptosis detection; Flow cytometry assay
• Mechanism Description: Andrographolide antagonizes the cigarette smoke-induced epithelial-mesenchymal transition and pulmonary dysfunction through anti-inflammatory inhibiting HOTAIR.

ICD-12: Respiratory system diseases

Chronic obstructive pulmonary disease [ICD-11: CA22]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: HOX transcript antisense RNA (HOTAIR) [1]

• Molecule Alteration: Up-regulation; Expression
• Resistant Disease: Chronic obstructive pulmonary disease [ICD-11: CA22.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: SV40 cells; N.A.; .; N.A.
• In Vivo Model: Male BALB/c mice moddel; Mus musculus
• Mechanism Description: Andrographolide antagonizes the cigarette smoke-induced epithelial-mesenchymal transition and pulmonary dysfunction through anti-inflammatory inhibiting HOTAIR.

References

• Ref 1: Andrographolide antagonizes the cigarette smoke-induced epithelial-mesenchymal transition and pulmonary dysfunction through anti-inflammatory inhibiting HOTAIRToxicology. 2019 Jun 15;422:84-94. doi: 10.1016/j.tox.2019.05.009. Epub 2019 May 23.